Therapeutic efficacy and safety of artemether-lumefantrine for the treatment of uncomplicated falciparum malaria in North-Eastern Tanzania by Alex Shayo et al.
Shayo et al. Malaria Journal 2014, 13:376
http://www.malariajournal.com/content/13/1/376RESEARCH Open AccessTherapeutic efficacy and safety of
artemether-lumefantrine for the treatment
of uncomplicated falciparum malaria in
North-Eastern Tanzania
Alex Shayo1, Celine I Mandara2, Francis Shahada1, Joram Buza1, Martha M Lemnge2 and Deus S Ishengoma2*Abstract
Background: The World Health Organization recommends that regular efficacy monitoring should be undertaken
by all malaria endemic countries that have deployed artemisinin combination therapy (ACT). Although ACT is still
efficacious for treatment of uncomplicated malaria, artemisinin resistance has been reported in South East Asia
suggesting that surveillance needs to be intensified by all malaria endemic countries. This study assessed the
efficacy and safety of artemether-lumefantrine (AL) for the treatment of uncomplicated falciparum malaria in
Muheza district of north-eastern Tanzania, an area where the transmission has significantly declined in recent years.
Methods: Eighty eight children (aged 6 months to 10 years) with uncomplicated falciparum malaria were recruited
into the study. The patients were treated with standard doses of AL and followed up for 28 days. The primary end
point was parasitological cure on day 28 while the secondary end points included: improvement in haemoglobin
levels and occurrence, and severity of adverse events.
Results: A total of 163 febrile patients were screened, out of which 88 patients (56 under-fives and 32 aged ≥5 years)
were enrolled and 79 (89.8%) completed the 28 days of follow-up. There were no cases of early treatment failure
whilst 40 (78.4%) under-fives and 21(75.0%) older children had adequate clinical and parasitological response
(ACPR) before PCR correction. Late clinical failure was seen in 5.6% (n = 51) and 3.6% (n = 28) of the under-fives and
older children respectively; while 15.7% and 21.6% had late parasitological failure in the two groups respectively.
After PCR correction, ACPR was 100% in both groups. Reported adverse events included cough (49.7%), fever (20.2%),
abdominal pain (10.1%), diarrhoea (1.3%), headache (1.3%) and skin rashes (1.3%).
Conclusion: This study showed that AL was safe, well-tolerated and efficacious for treatment of uncomplicated
falciparum malaria. Since Muheza has historically been a hotspot of drug resistance (e.g. pyrimethamine, chloroquine,
and SP), surveillance needs to be continued to detect future changes in parasite sensitivity to ACT.
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Despite the current reported declining trends, malaria
has remained an important public health problem and
the main cause of morbidity and mortality in Tanzania
and elsewhere in sub-Saharan Africa (SSA). Globally, an
estimated 3.4 billion people were at risk of malaria and* Correspondence: deusishe@yahoo.com
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Of the reported deaths, 90% occurred in SSA and major-
ity involved children less than five years of age [1]. Apart
from other strategies, malaria control still relies on early
diagnosis and prompt treatment with efficacious drugs;
and artemisinin-based combination therapy (ACT) is
currently the cornerstone of malaria case management
[2,3]. Currently, ACT remains highly effective in almost
all settings, as long as the partner drug in the combin-
ation is locally effective. However, the recently reportedtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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Asia (Cambodia, Myanmar, Thailand and Vietnam) is a
major concern for the global effort to control malaria.
There is an urgent need to implement/continue with
therapeutic efficacy testing (TET) in all countries which
have deployed ACT as recommended by the World
Health Organization (WHO) [1]. It is also crucial to in-
tensify the surveillance of artemisinin resistance and ex-
pand containment to prevent the spread of resistance to
other countries, as recommended within the WHO global
plan for artemisinin resistance containment(GPARC) [4].
Following the establishment of the East Africa Network
for Monitoring Antimalarial Treatment (EANMAT) in
1997, Tanzania through its National Malaria Control
Programme (NMCP) has been routinely conducting TETs
at eight sentinel sites located in different parts of the
country [5]. The efforts by NMCP have also been comple-
mented by trials conducted by independent researchers.
The findings of these trials provided useful data to support
changes of anti-malarial drug policy in Tanzania; including
changes from choloroquine (CQ) to sulphadoxine-pyri-
methamine (SP) in 2001 [6] and SP to artemether-lumefan-
trine (AL) in 2006 [7]. However, few studies have been
conducted to monitor the efficacy of ACT after deployment
of AL in 2006 [7] and this has been partly due to lack
of funding and complacency attributed to perceived high
therapeutic efficacy of ACT.
Studies conducted in Tanzania before and after intro-
duction of ACT showed that AL has remained efficacious
and safe when used for treatment of uncomplicated mal-
aria in areas of different transmission intensity [8-11].
However, emergence of artemisinin resistance in South
East Asia [12] indicates that routine monitoring needs to
be urgently intensified in order to facilitate early detection
of emergence and spread of tolerance/resistance to ACT
in Tanzania and other malaria endemic countries. Such
surveillance would provide evidence for formulating miti-
gation and containment strategies as recommended by
WHO [4].
Furthermore, the recent decline in malaria transmis-
sion in majority of the malaria endemic countries sug-
gests that new strategies and changes in therapeutic
efficacy monitoring methods are urgently needed to en-
sure that monitoring of anti-malarial efficacy is routinely
conducted in a sustainable manner. Such changes might
include focusing on key areas in each country (e.g. areas
with high levels of migrations), changing the target popu-
lation (e.g. from under-fives to all age groups), reducing
the cut-off density of malaria parasite and prolonging the
study duration. The present study was conducted in an
area where malaria has progressively and significantly
declined in recent years [13] to compliment the efforts
of NMCP of surveillance of anti-malarial efficacy. The
study assessed the efficacy and safety of AL for treatmentof uncomplicated malaria in the area which is under re-
cent epidemiological transition from holo/hyper-endemic
to low malaria transmission. It therefore, provides updates
on the performance of AL after Tanzania adopted it as a
first-line drug for the treatment of uncomplicated falcip-
arum malaria [7] and in the perspectives of declining mal-
aria transmission in the country.
Methods
Study site, design and target population
The study was conducted between May and August
2013 at Mkuzi Health Centre in Muheza district, north-
eastern Tanzania. Mkuzi is one of the sentinel sites of
the NMCP where anti-malarial TET has been routinely
conducted since 1997 [5,14]. This site and other parts of
Muheza district have historically been known as a hotspot
for anti-malarial drug resistance in Tanzania; including
pyrimethamine [15], CQ [16,17], amodiaquine [18] and SP
[19-22]. Previous studies conducted in Muheza to test the
efficacy of different ACT showed that AL had high efficacy
while others such as artesunate + amodiaquine (ASAQ)
and artesunate + sulphadoxine-pyrimethamine (AS-SP)
had relatively low efficacy [23]. Furthermore, studies con-
ducted at Mkuzi in 2007, showed that ASAQ had lim-
ited clinical efficacy whereby PCR uncorrected outcome
of < 40% and PCR adjusted results of 80% were reported
(Ishengoma et al., unpublished observation).
This study was designed as a prospective, open-label,
non-randomized single-arm trial based on the WHO
protocol of 2009 [24]. Unlike previous studies, the current
study was conducted after the area had been reported to
have a progressively declining burden of malaria [13,25]
and thus the site was considered to be under transition
from high to moderate malaria transmission. The study
protocol was therefore modified as recommended by
WHO to include children aged six months to 10 years
and parasitaemia as low as 250 asexual parasites/μl of
blood [24].
Sample size estimation
The sample size was determined based on WHO stand-
ard protocol [24] whereby treatment failure of AL was
assumed to be 5%, with confidence level of 95% and a
precision around the estimate of 5%. The estimated sam-
ple was 79 patients and with a 20% increase to allow for
the loss to follow-up and withdrawals during the 28 days
of follow-up, 88 patients were included in the study [24].
Screening and recruitment
Children aged 6 months to 10 years who attended the
outpatient department of Mkuzi Health Centre were
screened, and those who met the eligibility criteria were
enrolled into the study. Inclusion criteria included
mono-infection of P. falciparum detected by microscopy,
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asexual forms per μl of blood and history of fever during
the past 24 hours or fever at presentation (axillary
temperature ≥ 37.5°C). Others were ability to swallow
oral medications; ability and willingness to attend sched-
uled follow-up visits, informed consent provided by parent
or guardian and stable residence within the catchment
area throughout the study period. Patients with general
danger signs or signs of severe falciparum malaria were
excluded from the study. Patients with mixed or mono-
infections with other Plasmodium species, presence of
severe malnutrition or febrile conditions due to diseases
other than malaria; and regular medication which might
have interfered with anti-malarial pharmacokinetics were
also excluded but received appropriate treatment accord-
ing to the national guidelines.
Laboratory screening involved a finger prick to collect
blood samples for detection of malaria parasites by rapid
diagnostic test (RDTs) and microscopy using thick and
thin smears. For patients with positive RDT results, the
blood slides were stained with 10% Giemsa for 10–15
minutes and examined to detect presence of malaria
parasites and the level of parasitaemia by microscopy.
Patients who met the inclusion criteria were enrolled in
the study and sent back to the laboratory for collection
of blood samples including two more blood slides, dried
blood spots (DBS) on filter papers, blood for haemoglo-
bin determination and collection of malaria parasites
for further analysis of P. falciparum diversity. One of
the two blood slides was stained with 3% Giemsa for
30–45 min and used to determine the actual parasite
density, species and presence of gametocytes. Parasitaemia
was measured by counting the number of asexual para-
sites against 200 white blood cells (WBCs) and sexual
parasites per 500 WBC in thick blood films and detection
of the different parasite species was done on thin films.
Parasite density per micro litre (μl) of blood was calcu-
lated by multiplying the total count by 40 for asexual and
16 for sexual parasites, assuming a putative mean count of
8,000 leucocytes/μl of blood [26]. When more than 500
parasites were identified before counting 200 leucocytes,
counting was stopped and parasitaemia was calculated as
stated above. A blood slide was declared negative when
examination of 200 high power fields did not reveal the
presence of malaria parasite.
Treatment and follow-up
Patients enrolled in the study were treated with AL
(Coartem®, Beijing Novartis Pharma Ltd, Beijing China
for Norvatis Pharma AG, Basle, Switzerland [manufac-
tured on August, 2012 and expiry date; July, 2014, Lot no:
X1606]), a fixed combination of 20 mg of artemether and
120 mg lumefantrine in a tablet. The drugs were adminis-
tered according to the recommended doses based on theweight of patient. One tablet was given to children weigh-
ing 5-14 kg; two tablets to children with 15–24 kg and
three tablets to children weighing 25–35 kg. A full course
of AL consisted of six doses given twice daily (8 hourly
apart for day 0 and 12 hourly apart for days 1 and 2).
Patients were observed for 30 minutes to ensure that they
did not vomit the study drugs. When vomiting occurred, a
repeat dose was given after vomiting stopped. Any patient
who persistently vomited the study medication, treatment
was discontinued and such patient was withdrawn from
the study, and treated with parenteral quinine according
to the national guidelines for management of complicated
and severe malaria. Paracetamol was given to all patients
with body temperature greater than or equal to 38°C. All
AL doses were administered orally under direct observa-
tion of a study nurse.
Follow-up was done for 28 days with scheduled visits
on days 0, 1, 2, 3, 7, 14, 21, and 28 or at any other day
(unscheduled visits) when patient felt unwell. Parents/
guardians were informed and encouraged to bring the
children to the clinic whenever they were unwell without
waiting for their scheduled visits. Patients who could not
come for their scheduled visit by mid day were visited at
home by a member of the study team and asked to come
to the health centre. Patients who travelled to other
places and could not be traced for scheduled follow-up
were withdrawn from the study. During the visits, both
clinical and parasitological assessments were performed;
and follow-up samples (blood slides, DBS, blood for
haemoglobin and parasite diversity) were also collected.
Sample processing and parasite genotyping
Human white blood cells (WBCs) were depleted using
CF11 cellulose columns [27] and parasite DNA was ex-
tracted from whole blood samples using QIAamp DNA
blood midi kits (Qiagen GmbH, Hilden, Germany) accor-
ding to the manufacturer’s instructions. Paired samples
(day 0 and parasites collected on or after day 14) were
genotyped by analysing the polymorphic loci of merozoite
surface proteins 1 and 2 (MSP1 and MSP2), and glutamate
rich protein (GLURP) to distinguish true recrudescent
from re-infections as previously described [28,29]. DNA
extracted from blood samples collected for parasite diver-
sity study will be sequenced at Sanger Institute, UK and
the findings including the prevalence of different muta-
tions associated with ACT resistance will be presented
elsewhere.
Outcome classification
The primary end point was parasitological cure on day
28 as per WHO protocol of 2009 [24] and secondary
end points included parasitological cure on day 14, im-
provement in haemoglobin levels at day 28 from the day 0
baseline, and occurrence and severity of adverse events.
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failure (ETF), late clinical failure (LCF), late parasitological
failure (LPF), and adequate clinical and parasitological
response (ACPR) before and after PCR correction [30].
Ethical considerations
Ethical clearance for this study was obtained from the
National Medical Research Coordination Committee of the
National Institute for Medical Research (NIMR-MRCC).
Permission to conduct the study in Muheza was sought in
writing from the relevant regional and district medical au-
thorities. Oral and written informed consent was obtained
from parents or guardians of all patients before they were
screened for possible inclusion into the study.
Data management and analysis
The data was entered (by double entry) into a Microsoft
Access database followed by validation and cleaning. Data
analysis was done using STATA for Windows, version 11
(STATA Corporation, TX-USA). Descriptive statistics as
percentages, mean, median, standard deviation, and range
were applied as appropriate. Treatment outcome was ana-
lysed based on per protocol method and Kaplan–Meier
analysis. Patients were stratified into two groups of chil-
dren aged ≥5 years and under-fives; and baseline charac-
teristics, primary and secondary outcomes were compared
between the two groups. Continuous variables such as
parasite density, age and haemoglobin concentrations
between the two groups were compared using t-test
(for normally distributed data) or Mann–Whitney U test
(a non-parametric test for non-normally distributed data).
For all statistical tests, p-value was set at 0.05.
Results
Baseline characteristics
A total of 163 febrile patients were screened for eligibility
to participate in the study whereby 90 (55.2%) patients
had malaria parasites by microscopy and 89 (54.6%) had
P. falciparum mono-infections. Of the P. falciparum
mono-infected patients, one had parasite density below
250 asexual parasites per microlitre and was therefore not
enrolled while 88 patients fulfilled the inclusion criteria
and were enrolled into the study. During follow-up, a total
of nine participants were lost to follow-up as they travelled
out of the study area, leaving 79 patients for further ana-
lysis of treatment outcome (Figure 1).
Forty six (52%) of the enrolled patients were males
and there were significantly more males among children
aged ≥5 years compared to under-fives (χ2 = 5.47, p = 0.019).
The overall mean body temperature at enrolment was
38.3 ± 1.3°C while the mean haemoglobin level was 10.4 ±
1.8 g/dl. The parasite density ranged from 256 to 200,000
with a geometric mean of 18,551 asexual parasites/μl. Allbaseline characteristics (except sex and age) were similar
in the two age groups (Table 1).
Treatment outcome
There were no cases of ETF while LCF was observed in
three (5.6%) and one (3.6%) cases among under-fives and
those aged ≥5 years, respectively (Table 2). Eight (15.7%)
and six (21.6%) patients among under-fives and those
aged ≥ 5 years, respectively, had LPF. Before PCR cor-
rection, ACPR was similar in both groups and after PCR
correction, all treatment failures were shown to be due to
new infections and, therefore, ACPR was 100% in both
groups (Table 2).
Parasite and fever clearance
A total of 68 (77.3%) patients had malaria parasites on day
1 post-treatment while 17(19.5%) had parasites on day 2
and only one patient (1.4%) had parasites on day 3.
Twenty three (26.1%) and 2 (2.3%) patients had fever on
day 1 and 2 respectively. Two patients (2.3%) still had
fever on day 3 post-treatment although the axillary tempe-
rature was low (≤37.9°C). There was no significant differ-
ence in parasite and fever clearance between under-fives
and children aged ≥ 5 years (Figures 2 and 3).
Haematological recovery
The mean haemoglobin at enrolment was 10.4 ± 1.8 g/dl
and showed an overall progressive increase from baseline
(day 0) to day 28 (day 0 vs day 28, p < 0.03) in both under-
fives and children aged ≥5 years. The haematological
recovery in children aged ≥5 years was statistically signifi-
cant (p = 0.006) while Hb recovery in under-fives was not
statistically significant (p = 0. 305) (Figure 4).
Safety
Overall, adverse events (AEs) reported were cough
(49.4%), fever (20.2%), abdominal pain (10.1%), diarrhoea
(1.3%), headache (1.3%) and skin rashes (1.3%). However,
most of the AEs occurred in under-fives compared to
older children aged ≥5 years (only 6% of the under-fives
had no AEs compared to about 36% of the older children).
There were no serious adverse events and all the AEs were
not related to the medications (Table 3).
Discussion
Due to high level of resistance to common and cheap
anti-malarial drugs, such as SP and CQ, Tanzania was
forced to change its malaria treatment guidelines twice
in a decade. The first change was done in 2001 to replace
CQ (which had been used for more than three decades)
with SP [6]. Because resistance to pyrimethamine which is
an important partner drug in SP had been reported
[21,31] and there were indications that resistance to SP
had started to emerge, the policy changes were adopted as
Figure 1 Profile of patients screened and enrolled in the study.
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in 2006 whereby SP was replaced with AL as the first-line
for treatment of uncomplicated malaria [7]. Because of the
threat of emergence and spread of artemisinin resistance
in malaria endemic countries especially in Africa, in-vivoTable 1 Baseline characteristics of study participants
Variable Overall
Number of patient enrolled (n) 88
Age in years, mean (SD) 4.6(2.5)
Weight (kg), mean (SD) 16.0(5.1
Sex (male)*, n (%) 46(52.3)
Body temperature, mean (SD) 38.3°C(1
Geometric mean parasite density (asexual parasite/ul), 95% CI† 18,603(1
Haemoglobin g/dL, mean (SD) 10.4(1.8
SD = Standard deviation, 95% CI = 95% confidence interval.
*There were significantly more males among children aged ≥5 years compared to u
† Only 4 patients had parasitaemia <1000 asexual parasites/μl; parasite density rang
and children aged ≥5 years respectively.anti-malarial TET is recommended for monitoring ACT
efficacy to ensure their long-term usefulness. Contrary to
the recommendations by WHO [24], surveillance of anti-
malarial resistance by the Tanzanian NMCP and its part-








nder-fives (χ2 = 5.47, p = 0.019).
ed from 256 to 200,000 and 480 to 197,440 asexual parasites/μl in under-fives
Table 2 Treatment outcome
Outcome PCR uncorrected PCR corrected
Under-fives (n = 51)*
Early Treatment Failure (ETF) 0 (0%) 0 (0%)
Late Clinical Failure (LCF) 3 (5.6%)*** 0 (0%)
Late Parasitological Failure (LPF) 8 (15.7%)*** 0 (0%)
Adequate Clinical and Parasitological Response (ACPR) 40 (78.4%) 40 (100%)
Children aged ≥5 years (n = 28)**
Early Treatment Failure (ETF) 0 (0%) 0 (0%)
Late Clinical Failure (LCF) 1 (3.6%)*** 0 (0%)
Late Parasitological Failure (LPF) 6 (21.6%)*** 0 (0%)
Adequate Clinical and Parasitological Response (ACPR) 21 (75.0%) 21 (100%)
Overall Adequate Clinical and Parasitological Response (ACPR) 61 (77.2/%) 61 (100/%)
*5 lost to follow-up, **4 lost to follow-up.
***PCR Genotyping showed that they were new infections.
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plement NMCP efforts with the aim of assessing the
therapeutic efficacy and safety of AL when used for treat-
ment of uncomplicated malaria in an area where malaria
transmission has significantly and progressively declined
in recent years [13,25].
The present study showed that the standard six-dose
of AL was efficacious for treatment of uncomplicated
P. falciparum malaria with rapid fever and parasite
clearance. Although the clinical efficacy was low (overall
PCR uncorrected ACPR = 77.2%), PCR corrected outcome
was higher in all children irrespective of age group
(ACPR = 100%). These findings are consistent with other
AL therapeutic efficacy studies conducted in TanzaniaFigure 2 Parasite clearance time (days) among patients treated withand elsewhere in SSA where PCR corrected ACPR was
96 - 100% [32-36]. The rates of re-infections in the present
study were relatively lower compared to previous studies
[37] and this could be attributed to the currently low mal-
aria transmission in the study area. However, the transmis-
sion of malaria observed during this period was higher
compared to the same period in 2011 whereby the study
conducted at the same site failed to recruit sufficient num-
ber of patients (the target was 88 children but only 31 chil-
dren were enrolled) over two months (Kabanywanyi et al.,
unpublished data). In the current study, a total of 88 chil-
dren were recruited in six weeks only, suggesting that local
heterogeneity and micro-epidemiological factors could be
the key drivers of malaria transmission in Muheza.AL at Mkuzi Health Centre.
Figure 3 Fever clearance time (days) among patients treated with AL at Mkuzi Health Centre. *Fever = axillary temperature ≥37.5°C.
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one patient (1.1%) had parasitaemia on day 3 post-
treatment. Studies conducted elsewhere showed similar
findings whereby <1.1% the children had parasite on
day three post-treatment [3,9]. Artemether-lumefantrine
achieves fast parasite clearance as a result of fast action of
artemisinins. Artemisinins are rapidly absorbed and the
short lived active metabolite, dihydroartemisinin quickly
reduces parasite biomass leading to prompt symptomatic
relief. The longer lived partner; lumefantrine, persists in
the blood eliminating any remaining parasite load and
thus preventing recrudescence. The observed fast parasitesFigure 4 Haemoglobin recovery in under-fives and children aged ≥5clearance in this study indicates that parasite tolerance/re-
sistance has not emerged and AL is still effective in the
treatment of uncomplicated falciparum malaria in the
study area. However, the observed levels of re-infections
suggest that lumefantrine may not be providing sufficient
protection against recurrent infections during the entire
period of follow-up.
The mean temperature of children recruited in the
study was high (38.5°C and 38.1°C in the under-fives
and children aged ≥5 years, respectively) and consistent
with the reports of studies conducted elsewhere in
Tanzania [10] and Ethiopia [38]. Fast fever clearanceyears treated with AL.
Table 3 Reported adverse events in both under-fives and
children aged 5-10 years
Adverse event Age groups Total
Under-fives
(n = 51)
Children aged ≥5 years
(n = 28)
Cough 28(54.9%) 11(39.3%) 39(49.4%)
Fever 13(25.5%) 3(10.7%) 16(20.2%)
Abdominal pain 5(9.8%) 3(10.7%) 8(10.1%)
Diarrhoea 1(2.0%) 0(0%) 1(1.3%)
Headache 0(0%) 1(3.6%) 1(1.3%)
Skin rashes 1(2.0%) 0(0%) 1(1.3%)
None 3(5.9%) 10(35.7%) 13(16.5%)
Total 51(100%) 28(100%) 79(100%)
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the children had cleared the fever within 48 hours. The
quick fever clearance could be explained by the fast acting
property of artemisinins which clear the parasites leading
to resolution of symptoms including fever [39].
The progressive haematological recovery post-treatment
suggests that malaria could be the major contributing
factors to the low haemoglobin levels at recruitment
especially in older children. Insignificant haematological
recovery irrespective of parasite clearance in the younger
children suggests that other factors, such as geohelminths,
may also play a key role in the chronicity of anaemia as
reported in other studies [3].
In the present study, adverse events were reported in
66 (75%) of the recruited children but they were mild
and not associated with the treatment. Cough was the
most frequent adverse event in both age groups, which
is in line with previous studies which showed that
respiratory infections are common in African children
with malaria [40]. Similar findings were also observed in
other studies conducted in Tanzania and Ethiopia, whereby
only mild adverse events were reported with cough as the
most frequent symptom [3,41]. However, since time to on-
set of cough was relatively evenly distributed throughout
the duration of the study, cough was probably not related
either to malaria or to AL treatment. Headache was only
reported in older children (aged ≥ 5 years) but this could
probably be attributed to increased ability to report symp-
toms. However, the cause of these adverse events and their
possible association with AL treatment could not be
established and they need to be further explored in future
efficacy studies.
Due to declining malaria transmission in Muheza dis-
trict and other parts of Tanzania [13,25], the study
protocol was modified to include children aged ≥5 year
and low parasite density (250–200,000 asexual parasites
per/μl) as recommended by WHO [24]. The current
declining trend in parasite prevalence in the study areaas previously reported implies that majority of the people
are experiencing low exposure to infections. This may
result into delayed development and overall reduction in
partial immunity to malaria [42,43]. In such settings,
besides children under-five years, older children (≥5-10
years) are also at higher risk of clinical malaria [44] and
treatment outcome among these two groups is not expec-
ted to be affected by the level of immunity. Furthermore,
the shifting in malaria burden from young to older chil-
dren as previously reported in the study area [45], was
expected to lead to more older children who would be
seeking treatment for malaria. In the contrary, this study
recruited more under-five children compared to those
aged ≥5 years and the baseline characteristics of the two
groups were similar. Furthermore, the efficacy of AL was
similar in the two groups.
However, there were more female children among
under-fives compared to older children aged ≥5 years. The
difference in the proportion of female and male in the
present study may simply be related to the difference in
health-seeking behaviour rather than actual difference in
disease prevalence as it has been reported elsewhere [38].
Although previous studies enrolled only children below
five years on the ground of low immunity to malaria, this
study shows that treatment response was not affected by
age. This indicates limited role of immunity in enhancing
treatment response which is contrary to previous studies
which showed that acquired immunity enhanced treat-
ment response even with resistant parasites [46]. On the
other hand, lowering the cut-off of parasite density to
250 asexual parasites/μl was expected to increase the
number of enrolled patients. It was observed that only
4 patients had parasite density ranging from 250 – 1000
and 9 had 250 – 2000 asexual parasites per/μl suggesting
that the decision to lower parasitaemia and inclusion of
children aged ≥5 years in anti-malarial clinical trials needs
to be further re-evaluated.
Conclusion
The efficacy of AL for treatment of uncomplicated mal-
aria was still high in the study area despite higher rates
of re-infection. Thus, despite the reported cases of late
clinical failure, these findings showed that AL was safe,
well tolerated and effective for treatment of uncompli-
cated P. falciparum malaria. With the recent reports of
declining trends in malaria prevalence in most parts of
Tanzania including north-eastern Tanzania, anti-malarial
drug pressure in the community has decreased and this
may possibly limit the occurrence and spread of parasite
tolerance/resistance to ACT. Despite such promising re-
ports, as the world strives to achieve malaria elimination,
further studies are needed to monitor efficacy of AL and
other ACT in order to provide evidence for timely review
of malaria treatment policy in the country. Since Muheza
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methamine, chloroquine, and SP), surveillance needs to be
continued at this and other sites in the country to detect
future changes in parasite sensitivity to ACT.
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